has just approved the drug Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) as treatment for people with ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

Aromatase inhibitors (AIs) are a class of drugs that block the aromatase enzyme, which is responsible for converting androgens (male hormones) into estrogens (female hormones). These medications ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

"What's important is that these drugs significantly reduce late recurrences," says Isaacs. But she notes that researchers still don't know which strategy works best: taking an aromatase inhibitor ...

Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastrozole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Do innovator drugs work better than generic ... Ask the Pharmacists, November 2010 Can the Duration of Aromatase Inhibitor Therapy Exceed 5 Years? Does extended-duration aromatase inhibitor ...

The new approval covers Kisqali's use in combination with an aromatase inhibitor (AI) in patients with HR+/HER2- early breast cancer at high risk of recurrence. Previously, the drug was approved ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Treatment with the aromatase inhibitor anastrozole decreased the ... (New York Times) Disparities in access to novel anti-obesity drugs could be made worse if the medications are denied to people ...